contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bergenbio-asa-bergenbio-asa-notice-of-extraordinary-general-meeting

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

BerGenBio

Bergen, Norway - 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 2024 at 10:00 hours (CEST).The notice, registration form...

<div class="abstract">Bergen, Norway - 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 2024 at 10:00 hours (CEST).</div>The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company's website: <a href="https://www.bergenbio.com/investors/general-meetings/">https://www.bergenbio.com/investors/general-meetings/</a>All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the person he appoints), or to attend the general meeting virtually. Advance vote or proxy for the Annual General Meeting can be registered through the company's website&nbsp;(<a href="https://www.bergenbio.com/investors/general-meetings/">https://www.bergenbio.com/investors/general-meetings/</a>) or VPS Investor Service&nbsp;(<a href="https://investor.vps.no/gm/logOn.htm?token=1c142f482991b4042a7a7f81406dafb4ce5e515d&amp;validTo=1731139200000&amp;oppdragsId=20240916VPK455U0">https://investor.vps.no/gm/logOn.htm?token=1c142f482991b4042a7a7f81406dafb4ce5e515d&amp;validTo=1731139200000&amp;oppdragsId=20240916VPK455U0</a>) within 8 October 2024 16:00 hours (CEST). Virtual participants need to be logged in to the meeting before 10:00 hours (CEST) 10 October 2024.All shareholders will receive a reference number and a pin code required for registration through the company's website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user. We encourage all shareholders to register as electronical user in VPS.- END -AboutBerGenBioASABerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.comContactsMartin Olin, CEO, BerGenBio ASA ir@bergenbio.comRune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.comForward looking statementsThis announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Stay up to date with our newsletter